Drug Profile
Voruciclib - MEI Pharma
Alternative Names: ME-522; P 1446A 05; P-1446; P1446A; VoruciclibLatest Information Update: 13 Dec 2023
Price :
$50
*
At a glance
- Originator Piramal Life Sciences
- Developer MEI Pharma; Piramal Enterprises
- Class Antineoplastics; Benzopyrans; Pyrones; Pyrrolidines; Small molecules
- Mechanism of Action CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; B-cell lymphoma
- No development reported Malignant melanoma
Most Recent Events
- 11 Dec 2023 Adverse events, efficacy, pharmacodynamics and pharmacokinetics data from a phase I trial in Acute myeloid leukemia, B-cell lymphoma, Mantle-cell lymphoma, Follicular lymphoma, Diffuse large B cell lymphoma and Chronic lymphocytic leukaemia released by MEI Pharma
- 09 Dec 2023 Updated efficacy, adverse event and pharmacokinetic data from a phase I trial in Acute myeloid leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
- 26 Sep 2023 Voruciclib is still in phase Ib trial for Acute myeloid leukemia, B-cell lymphoma (Monotherapy, Combination therapy, Second-line therapy or greater) in USA (PO, Capsule) (NCT03547115)